Funds and ETFs Precision BioSciences, Inc.

Precision BioSciences, Inc is a clinical-stage gene editing company. It is developing ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases with the application of its owned ARCUS genome editing platform. ARCUS is designed to be precise in its specificity and versatile in its design for gene knock out as well as complex edits with gene insertion and gene repair. ARCUS is also relatively small size, which potentially allows delivery to a range of cells and tissues using viral and non-viral gene delivery methods. Genome editing is a biotechnology process that removes, inserts or repairs a portion of deoxyribonucleic acid (DNA) at a specific location in a cell's genome. There are two primary mechanisms of DNA repair, non-homologous end joining, and homology directed repair. There are several genomes editing technologies, including ARCUS, zinc-finger nucleases, TAL-effector nucleases, CRISPR/Cas9, and base editors.